Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® System

Author： Hermida-Cadahia Esperanza F.   Tutor J. Carlos  

Publisher： Informa Healthcare

ISSN： 0036-5513

Source： Scandinavian Journal of Clinical and Laboratory Investigation, Vol.72, Iss.2, 2012-04, pp. : 180-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 1600-6135, Iss. 10, 2015-10 ,pp. : 2655-2664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 10, 2015-10 ,pp. : 2655-2664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 8, 2015-08 ,pp. : 1056-1065

John Wiley & Sons Inc

Access to resources Recommend Favorite

Conversion to a sirolimus‐based regimen is associated with lower incidence of BK viremia in low‐risk kidney transplant recipients

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 17, Iss. 1, 2015-02 ,pp. : 66-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Belatacept for kidney transplant recipients

By  

NEPHROLOGY, Vol. 20, Iss. 10, 2015-10 ,pp. : 752-754

John Wiley & Sons Inc

Access to resources Recommend Favorite